A erythrocyte-platelet hybrid membrane coated biomimetic nanosystem based on ginsenosides and PFH combined with ultrasound for targeted delivery in thrombus therapy

• Published in: Colloids and surfaces, B, Biointerfaces B, Biointerfaces, 2023-09, Vol.229, p.113468-113468, Article 113468
• Main Authors: Yang, Ming-Yue, Tu, Yi-Fan, Feng, Ke-Ke, Yin, Meng-Die, Fang, Yi-Fan, Le, Jing-Qing, Luo, Bang-Yue, Tan, Xia-Rong, Shao, Jing-Wei
• Format: Article
• Language: English
• Subjects: Biomimetic nanosystem; Ginsenoside; Perfluorohexane; Thrombotic diseases
• ISSN: 0927-7765; 1873-4367
• DOI: 10.1016/j.colsurfb.2023.113468

Thrombus is one of the culprits for global health problems. However, most current antithrombotic drugs are limited by restricted targeting ability and a high risk of systemic bleeding. A hybrid cell membrane-coated biomimetic nanosystem (PM/RM@PLGA@P/R) was constructed in this paper to fulfil the targeted delivery of ginsenoside (Rg1) and perfluorohexane (PFH). Poly lactic-co-glycolic acid (PLGA) is used as carriers to coat Rg1 and PFH. Thanks to the camouflage of erythrocyte membrane (RM) and platelet membrane (PM), the nanosystem in question possesses remarkable features including immune escape and self-targeting. Therefore, a compact nano-core with PLGA@P/R was formed, with a hybrid membrane covering the surface of the core, forming a “core-shell” structure. With its “core-shell” structure, this nanoparticle fancifully combines the advantages of both PFH (the low-intensity focused ultrasound (LIFU)-responsive phase-change thrombolysis) and Rg1(the antioxidant, anti-inflammatory and anticoagulant abilities). Meanwhile, PM/RM@PLGA@P/R nanoparticles exhibits superior in-vitro performance in terms of ROS scavenging, anticoagulant activity and immune escape compared with those without cell membranes (PLGA@P/R). Furthermore, in the animal experiment in which the tail vein thrombosis model was established by injecting k-carrageenan, the combined treatment of LIFU and PM/RM@PLGA@P/R showed a satisfactory antithrombotic efficiency (88.20 %) and a relatively higher biological safety level. This strategy provides new insights into the development of more effective and safer targeted biomimetic nanomedicines for antithrombotic treatments, possessing potential application in synergistic therapy field. [Display omitted] •Nanoparticles coated with hybrid cell membranes exhibited excellent targeting and immune evasion performance.•Rg1 and PFH achieved synergistic effect in treating thrombus.•PM/RM@PLGA@P/R nanoparticles possessed a high thrombus inhibition rate of 88.20 %.